Bruno Rotoli

Bruno Rotoli

Auto-generated profile, based on publicly available information

Bruno Rotoli

Sc Med. Univ Napoli, Naples, Italy

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
Marco PicardiMarco Picardi
Marco Picardi
ARAmalia De Renzo
Amalia De Renzo
FPFabrizio Pane
Fabrizio Pane
ENEmanuele Nicolai
Emanuele Nicolai
RPRoberto Pacelli
Roberto Pacelli
BRBruno Rotoli
Bruno Rotoli
This study aimed at evaluating the role of consolidation radiation in a setting of Hodgkin's lymphoma (HL) patients, using event-free survival (EFS) as end point. Among 260 patients treated with induction chemotherapy for bulky HL, 160 patients achieved negative residual masses at 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) scans. They were randomly divided into two well-matched groups to receive either 32 Gy radiotherapy to bulky area or no further therapy. At a median follow-up of 40 months, histology showed a malignancy in 14% of patients in the chemotherapy-only group (HL, 11 patients) and in 4% of patients in the chemotherapy + radiotherapy group (HL, 2 patients; carcinoma in previously irradiated area, 1 patient) (P = 0.03). All the relapses in the chemotherapy-only group involved the bulky site and the contiguous nodal regions. Thus, the overall diagnostic accuracy of FDG-PET to exclude future relapses in the patients nonprotected by radiotherapy was 86% with a false-negative rate of 14%. Our study suggests that the addition of irradiation helps improve EFS in HL patients with post-chemotherapy FDG-PET-negative residual masses.

1 December 2004 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
BRBruno Rotoli
Bruno Rotoli
LCLucio Catalano
Lucio Catalano
MGMaurizio Galderisi
Maurizio Galderisi
LLLuigia Luciano
Luigia Luciano
GPGiuditta Pollio
Giuditta Pollio
APAntonio Pinto
Antonio Pinto
Endomyocardial fibrosis (Loeffler's endocarditis) is the main cause of poor outcome in Hyper Eosinophilic Syndrome (HES) and Eosinophilic Leukemia (EL). Reversion of the cardiac damage has been seldom reported, and thrombi can superimpose on infiltrated walls, originating oembolic complications. The tyrosine kynase inhibitor imatinib has been recently employed in patients affected by HES or EL, with impressive results. We have treated with imatinib a young patient affected by Loeffler's endocarditis during EL. Loeffler's endocarditis was studied by transthoracic Doppler echocardiography with and without the contrast agent SonoVue. Cytogenetics, FISH and molecular analysis showed the presence of the FIP1L1/PDGFRA fusion gene, recently detected in a majority of HES patients. Standard echocardiography revealed a large infiltration of the apical region, with apparently pedunculate corpora floating in the LV chamber; after SonoVue injection, a thick endo-myocardial infiltration involving papillary muscles and tendinous chords appeared, which simulated mobile thrombi at standard echography. Treatment with low dose imatinib caused rapid regression of both eosinophilic proliferation and endomyocardiopathy. The fusion gene FIP1L1-PDGFRA was found significantly decreased after a few months of treatment. Using a contrast echocardiographic approach, we demonstrated the non-thrombotic origin of the "in plus" image in our patient and its rapid resolution following imatinib treatment. Imatinib is an excellent candidate for first line treatment of Loeffler's endocarditis, especially when the FIP1L1/PDGFA fusion gene is detected.

16 August 2008 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
ACAndrea Camera
Andrea Camera
CRCiro R. Rinaldi
Ciro R. Rinaldi
SPSalvatore Palmieri
Salvatore Palmieri
NCNicola Cantore
Nicola Cantore
GMGiada Mele
Giada Mele
FFFelicetto Ferrara
Felicetto Ferrara

15 July 2006 in Transplantation
Verified
Journal Article
Closed access
Marco PicardiMarco Picardi
Marco Picardi
GRGennaro De Rosa
Gennaro De Rosa
CSCarmine Selleri
Carmine Selleri
FPFabrizio Pane
Fabrizio Pane
BRBruno Rotoli
Bruno Rotoli
PMPietro Muretto
Pietro Muretto
Hepatitis flare-up due to hepatitis B virus (HBV) is a well-recognized complication associated with chemotherapy. Data on the clinical impact of HBV DNA in liver tissue of HB-surface antigen (sAg)-negative patients undergoing immunosuppression are scanty

1 July 2003
Verified
Journal Article
Closed access
Marco PicardiMarco Picardi
Marco Picardi
GRGennaro De Rosa
Gennaro De Rosa
CSCarmine Selleri
Carmine Selleri
NSNicola Scarpato
Nicola Scarpato
ESErnesto Soscia
Ernesto Soscia
BRBruno Rotoli
Bruno Rotoli

31 March 2012 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
MHMarysia Hengeveld
Marysia Hengeveld
SSStefan Suciu
Stefan Suciu
MKMatthias Karrasch
Matthias Karrasch
GSGiorgina Specchia
Giorgina Specchia
JMJean-Pierre Marie
Jean-Pierre Marie
TWTheo de Witte
Theo de Witte
Summary The most effective post-remission treatment to maintain complete remission (CR) in adults aged between 46 and 60 years with acute myeloid leukaemia (AML) is uncertain. Previously untreated patients with AML in CR after induction chemotherapy with daunorubicin and cytarabine were randomized between two intensive courses of consolidation therapy containing high-dose cytarabine, combined with amsacrine or daunorubicin and a standard consolidation and maintenance therapy containing standard dose cytarabine and daunorubicin. One hundred fifty-eight CR patients were assigned to the intensive group and 157 patients to the standard group. After a median follow-up of 7.5 years, the 4-year survival rate was 32 % in the intensive group versus 34 % in the standard group (P = 0.29). In the intensive group, the 4-year relapse incidence was lower than in the standard group: 55 and 75 %, respectively (P = 0.0003), whereas treatment-related mortality incidence was higher: 22 versus 3 % (P < 0.0001). Two intensive consolidation courses containing high-dose cytarabine as post-remission treatment in patients with AML aged between 46 and 60 years old did not translate in better long-term outcome despite a 20 % lower relapse incidence. Better supportive care and prevention of treatment-related complications may improve the overall survival after intensified post-remission therapy in this age group.